238 related articles for article (PubMed ID: 28473707)
1. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.
Lund RJ; Huhtinen K; Salmi J; Rantala J; Nguyen EV; Moulder R; Goodlett DR; Lahesmaa R; Carpén O
Sci Rep; 2017 May; 7(1):1469. PubMed ID: 28473707
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
[TBL] [Abstract][Full Text] [Related]
3. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
4. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
5. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
[TBL] [Abstract][Full Text] [Related]
6. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
7. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
9. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance.
Sung HY; Han J; Chae YJ; Ju W; Lee Kang J; Park AK; Ahn JH
BMB Rep; 2023 Jun; 56(6):347-352. PubMed ID: 37013346
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
14. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
15. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
18. Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.
Gallon J; Loomis E; Curry E; Martin N; Brody L; Garner I; Brown R; Flanagan JM
Clin Epigenetics; 2021 Jun; 13(1):122. PubMed ID: 34090482
[TBL] [Abstract][Full Text] [Related]
19. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
[TBL] [Abstract][Full Text] [Related]
20. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.
Han X; Zhou Y; You Y; Lu J; Wang L; Hou H; Li J; Chen W; Zhao L; Li X
Cell Biol Int; 2017 Apr; 41(4):405-414. PubMed ID: 28150354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]